10.1002/dmrr.2502 122
Gao L, Huang H, Zhang L, Zhang N, Fu Y, Zhu D, et al
Additionally, the significant reductions in WC and WHR align with the body of evidence suggesting that the visceral fat is a major contributor to the metabolic complications associated with PCOS, and GLP-1RAs can help target this specifically
Results from the SURMOUNT-5 RCT are anticipated to be available this year and will reflect a direct comparison of tirzepatide 15 mg and semaglutide 2.4 mg weekly.193 One head-to-head trial compared orlistat to liraglutide at up to 1 year and found that patients on liraglutide lost 3.8 kg more than those on orlistat.144 Treatment Adjuncts to Pharmacological Agents in Obesity A proposed framework for treating obesity is outlined in Figure 4
When your stomach empties more slowly, everything downstream slows too
Today, the FDA-approved indications for this class span seven distinct clinical areas, and the investigational signals keep expanding